Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1600 participants.

Also called NCT02231138

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02231138
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02231138. Allocation not applicable; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2016-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
Intervention (Drug)
Abelmoschus manihot (AM)
Lead sponsor
Chinese PLA General Hospital (class: other)
Collaborator
Jiangsu Suzhong Pharmaceutical Group Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02231138
Content hash
9ac705e6447d0930f264dd8bd970efa31529d232cd22e31524af33fda33d037e